Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

PROSTATE CANCER

Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer

Nature Reviews Urology volume 18, pages 255–256 (2021)Cite this article

Subjects

Genomic alterations in metastatic castration-resistant prostate cancer can be identified in plasma circulating tumour DNA. A large cohort analysis shows reliable detection of clinically relevant alterations through targeted cell-free DNA sequencing with a commercial platform, paving the way for liquid biopsy technology to be integrated into routine clinical practice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Consistent detection of DNA damage repair defects in patient-matched liquid biopsy and tissue biopsy samples.

References

  1. Merseburger, A. S. et al. Genomic testing in patients with metastatic castration-resistant prostate cancer: a pragmatic guide for clinicians. Eur. Urol. 79, 519–529 (2021).

    Article  CAS  Google Scholar 

  2. Gonzalez, D. et al. Practical considerations for optimising homologous recombination repair mutation testing in patients with metastatic prostate cancer. J. Pathol. Clin. Res. https://doi.org/10.1002/cjp2.203 (2021).

    Article  PubMed  Google Scholar 

  3. Maia, M. C., Salgia, M. & Pal, S. K. Harnessing cell-free DNA: plasma circulating tumour DNA for liquid biopsy in genitourinary cancers. Nat. Rev. Urol. 17, 271–291 (2020).

    Article  Google Scholar 

  4. Wyatt, A. W. et al. Concordance of circulating tumour DNA and matched metastatic tissue biopsy in prostate cancer. J. Natl Cancer Inst. 109, djx118 (2017).

    Article  Google Scholar 

  5. Tukachinsky, H. et al. Genomic analysis of circulating tumor DNA in 3,334 patients with advanced prostate cancer identifies targetable BRCA alterations and AR resistance mechanisms. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-4805 (2021).

    Article  PubMed  Google Scholar 

  6. Mateo, J. et al. Genomics of lethal prostate cancer at diagnosis and castration resistance. J. Clin. Invest. 130, 1743–1751 (2020).

    Article  CAS  Google Scholar 

  7. Warner, E. et al. BRCA2, ATM, and CDK12 defects differentially shape prostate tumor driver genomics and clinical aggression. Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-20-3708 (2021).

    Article  PubMed  Google Scholar 

  8. Swanton, C. et al. Prevalence of clonal hematopoiesis of indeterminate potential (CHIP) measured by an ultra-sensitive sequencing assay: exploratory analysis of the Circulating Cancer Genome Atlas (CCGA) study. J. Clin. Oncol. 36 (Suppl. 15), 12003 (2018).

    Article  Google Scholar 

  9. Jensen, K. et al. Association of clonal hematopoiesis in DNA repair genes with prostate cancer plasma cell-free DNA testing interference. JAMA Oncol. 7, 107–110 (2021).

    Article  Google Scholar 

  10. Abida, W. et al. Genomic correlates of clinical outcome in advanced prostate cancer. Proc. Natl Acad. Sci. USA 116, 11428–11436 (2019).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Vancouver Prostate Centre, Department of Urologic Sciences, University of British Columbia, Vancouver, BC, Canada

    Sarah W. S. Ng & Alexander W. Wyatt

Authors
  1. Sarah W. S. Ng
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alexander W. Wyatt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alexander W. Wyatt.

Ethics declarations

Competing interests

A.W.W. reports receiving a commercial research grant from Janssen and honoraria from AstraZeneca, Astellas, Janssen and Merck. S.W.S.N. declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ng, S.W.S., Wyatt, A.W. Building confidence in circulating tumour DNA assays for metastatic castration-resistant prostate cancer. Nat Rev Urol 18, 255–256 (2021). https://doi.org/10.1038/s41585-021-00455-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41585-021-00455-3

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer